{"id":798818,"date":"2025-01-08T07:14:08","date_gmt":"2025-01-08T12:14:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"modified":"2025-01-08T07:14:08","modified_gmt":"2025-01-08T12:14:08","slug":"atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Jan.  08, 2025  (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43<sup>rd<\/sup>\u00a0Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA.<\/p>\n<p>A live webcast of the presentation will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-tG4-yT__OfF9q45m93txW1-oypqb4YIUvXG6UFBmRUVpwrTheqyHVSM307Nx6V7gcX3WfqSnXsKyerUiXJWrHw2gCrAJZ3NgSopBevylWaK92BpbkLlyKDzV9UwKobkdnZZddZebq8DnmevpLK_qhDOosY2EP46RybAwx3tFRsp8Km5IX4w4wPslBQLAokXJDL_vtelMj_LGq7bQVhFiw==\" rel=\"nofollow\" target=\"_blank\">here<\/a> and on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2RewoMcIyjVZKEsKS22OauwBEkaN-xsGeWDYA2iyBViTcFcZZajZOnuFqrj1uleL0DXdANGXzf06KQ2yHzJGWKEbLeHLUjNrF9hH-B7xMKVL_Ke7sfi9QjD0flLhtnvHjjj5iMatAfqAMzjt4u3aIbezb9ttxKofkQNSvIml3x8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.ateapharma.com<\/a>. An archived webcast will be available on Atea Pharmaceuticals\u2019 website for at least 90 days following the event.<\/p>\n<p>\n        <strong>About Atea Pharmaceuticals<\/strong>\n      <\/p>\n<p>Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea\u2019s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0stdZxXf_gWncSjTm0mhA8gJLlm3DJw_zzPZcHrG_VXb7zwrZWFNgQ22nZkpd6G7zQKwI3A29UocAVOoPk4m6QPN-BoM2PfXwTtAXNNBcj57PkAqgnp4LWVq9F9qI4P3nbQ0nvrhtywLC_wbJzXZH0o8cST_l8acDSGokkygKwjpMTkRJ7Kns6uKF1U0I-ZXEpZq8HFoceAmRC99y8ydxUhY-UsG3PQnBOa-k7V7AyQHMkgm1qDd4nSquYfyqNTmH0urEFihAN0bjTNzvPamx2jmDkkvuv8-DH3ay0pkiAJdrTsQg0_JKJptV9N-qO7K6fYYByI9jVViLkBtfZI2fr4XwqyepVM_BpmB2Ng80skx900TMSsC5f3i3ZCYxw2G1BsAZ7EAdHssz-0cZJ_6vsPAs_DHYWE5Es9FxFRmpgvbn6M8hxocMlJetSFt4kGZQnqMstMGuaILqcaOooXyqaPMWv-6KmkN9B19Gif3qZ8=\" rel=\"nofollow\" target=\"_blank\">www.ateapharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release includes \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the anticipated date and time of the Company\u2019s presentation at the conference. When used herein, words including \u201cexpects,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201canticipates,\u201d \u201cplans,\u201d and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company\u2019s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption \u201cRisk Factors\u201d in the reports the Company files with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC\u2019s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Jonae Barnes<br \/>SVP, Investor Relations and Corporate Communications<br \/>617-818-2985<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=28nMHZYccxM1WjAixh7aNw2YPp1BDc8XFaIpcJ3GBEbmje51ZR_ahQANf6gc0tFM7ZkMToKsjqD13zu8mE5MZc34oL2-8uxpzg5We8R6pImvnWFix4Lqfg5EGklxXhnx\" rel=\"nofollow\" target=\"_blank\">Barnes.jonae@ateapharma.com<\/a><\/p>\n<p>Will O\u2019Connor<br \/>Precision AQ<br \/>212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9GF82FTydOAkWE6AHIGvOy9zirKyK7idBuZh60PZssdbXLNGm6B_l_NqSUwbUtn3w5bcu595v6ZBoEvKu_HmOlXaGWpqEp2JHRv_aj-35XXsuv-w6IvO3FElejJJs5ig\" rel=\"nofollow\" target=\"_blank\">will.oconnor@precisionaq.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTgxM2MyMzctOGZkYS00MjFlLWJmOTUtMDkyMDA4YTllMTQ2LTEyMDkwMzQ=\/tiny\/Atea-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd\u00a0Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company\u2019s website at https:\/\/ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals\u2019 website for at least 90 days following the event. About Atea Pharmaceuticals Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798818","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd\u00a0Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company\u2019s website at https:\/\/ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals\u2019 website for at least 90 days following the event. About Atea Pharmaceuticals Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral &hellip; Continue reading &quot;Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T12:14:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2025-01-08T12:14:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":618,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=\",\"datePublished\":\"2025-01-08T12:14:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (\u201cAtea\u201d), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd\u00a0Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company\u2019s website at https:\/\/ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals\u2019 website for at least 90 days following the event. About Atea Pharmaceuticals Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral &hellip; Continue reading \"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T12:14:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference","datePublished":"2025-01-08T12:14:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"},"wordCount":618,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/","name":"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=","datePublished":"2025-01-08T12:14:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzkxNiM2NjgyNTkxIzIxOTc0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atea-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798818"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798818\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}